TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target

Lin Yu Chen, Rui Lan Huang, Michael W.Y. Chan, Pearlly S. Yan, Tien Shuo Huang, Ren Chin Wu, Yohan Suryo Rahmanto, Po Hsuan Su, Yu Chun Weng, Jian Liang Chou, Tai Kuang Chao, Yu Chi Wang, Ie Ming Shih, Hung Cheng Lai

研究成果: 雜誌貢獻文章同行評審

13 引文 斯高帕斯(Scopus)

摘要

Ten-eleven translocation methylcytosine dioxygenase-1, TET1, takes part in active DNA demethylation. However, our understanding of DNA demethylation in cancer biology and its clinical significance remain limited. This study showed that TET1 expression correlated with poor survival in advanced-stage epithelial ovarian carcinoma (EOC), and with cell migration, anchorage-independent growth, cancer stemness, and tumorigenicity. In particular, TET1 was highly expressed in serous tubal intraepithelial carcinoma (STIC), a currently accepted type II EOC precursor, and inversely correlated with TP53 mutations. Moreover, TET1 could demethylate the epigenome and activate multiple oncogenic pathways, including an immunomodulation network having casein kinase II subunit alpha (CK2α) as a hub. Patients with TET1 high CK2α high EOCs had the worst outcomes, and TET1-expressing EOCs were more sensitive to a CK2 inhibitor, both in vitro and in vivo. Our findings uncover the oncogenic and poor prognostic roles of TET1 in EOC and suggest an unexplored role of epigenetic reprogramming in early ovarian carcinogenesis. Moreover, the immunomodulator CK2α represents a promising new therapeutic target, warranting clinical trials of the tolerable CK2 inhibitor, CX4945, for precision medicine against EOC.
原文英語
頁(從 - 到)363-376
頁數14
期刊Journal of Pathology
248
發行號3
DOIs
出版狀態已發佈 - 7月 2019

ASJC Scopus subject areas

  • 病理學與法醫學

指紋

深入研究「TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target」主題。共同形成了獨特的指紋。

引用此